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Summary The reactivity of alpha-l-antitrypsin (AAT) with Lens culinaris agglutinin (LCA) was studied by
crossed immuno-affinity electrophoresis of the sera of 246 subjects from 6 groups (acute virus hepatitis,
chronic hepatitis, liver cirrhosis, hepatocellular carcinoma (HCC), carcinoma metastatic to the liver and
normal controls). Two species of AAT (LCA-reactive and -nonreactive species) were detected on crossed
immuno-affinity electrophoresis in a gel containing LCA. The percentages of LCA-reactive species of AAT in
neoplastic diseases of the liver were significantly higher than those in benign liver diseases and normal
controls. There was no correlation between the percentage of LCA-reactive species of AAT and serum AAT
concentration in any group. Furthermore, in studying 15 pairs of serum samples before and after the subsequent
development of HCC, the percentage of LCA-reactive species of AAT after HCC occurrence was significantly
higher than that before, although there was no statistically significant difference between the serum AAT
concentration before and after development of the disease. The latter 15 patients were all of the normal
protease inhibitor phenotype (PiMM) and no change in phenotype was observed before and after the
development of HCC. The results indicate that measurement of the reactivity of AAT with LCA can be a
useful marker for the diagnosis of HCC and carcinoma metastatic to the liver, especially when serum
concentrations of alpha-foetoprotein or other tumour markers are within the normal ranges.
Alpha-1-antitrypsin (AAT), one of the most important serum
protease inhibitors, neutralizes the activity of enzymes such
as elastase, trypsin and chymotrypsin, and is known as an
acute phase reactant. Genetical polymorphism of AAT was
reported by many investigators and about 30 genetic variants
have been recognized (Carrel et al., 1982). Hereditary
deficiency is predisposed to degenerative lung disease, and in
some instances, to liver disease (Laurell & Eriksson, 1963;
Sharp et al., 1969).
An increased incidence of hepatocellular carcinoma (HCC)
in adults with Pi (protease inhibitor) ZZ has been reported
(Berg & Eriksson, 1972; Eriksson & Hagerstrand, 1974).
This genetic deficiency is virtually confined to Europeans,
some 10% of whom are carriers of a pathological variant
(Carell et al., 1982). However, approximately 99% of the
general population have the normal protease inhibitor
phenotype (PiMM) in Japan (Miyake et al., 1980).
Early detection of HCC is very important during the
follow-up of patients with chronic liver diseases. The
measurement of serum alpha-foetoprotein (AFP)
concentration has been used extensively for the detection of
HCC. Furthermore, our previous studies have shown that
measurement of the fucosylated fraction of AFP is very
useful for the early diagnosis of HCC and that it can
distinguish an AFP species due to malignancy from one due
to benign liver diseases (Aoyagi et al., 1984, 1985a,b, 1986).
There are, however, also HCCs, the corresponding serum
AFP concentrations of which are within the normal range.
In this paper, we tested the reactivity of AAT with Lens
culinaris agglutinin (LCA) to evaluate its usefulness in the
diagnosis of liver diseases, and we found that measurement
of LCA-reactive species of AAT could be utilized for the
diagnosis of neoplastic diseases of the liver.
were included in group 1, 33 with chronic hepatitis (19,
chronic active hepatitis; 14, chronic inactive hepatitis) in
group 2, 54 with liver cirrhosis in group 3, 71 with HCC in
group 4, 23 with carcinoma metastatic to the liver in group 5
and 32 normal controls in group 6. In groups 2, 3, 4 and 5,
diagnosis was established by histology. Carcinoma metastatic
to the liver comprised 10 patients with gastric cancer, 5 with
gall bladder cancer, 1 with bile duct cancer, 3 with colon
cancer, 2 with pancreatic cancer, 1 with breast cancer and I
with cancer of unknown origin. The liver function tests of
normal controls were within the normal ranges, and they
had no history of liver diseases. In acute virus hepatitis,
aspartate aminotransferase or alanine aminotransferase was
>1000 IUI1 in 17 patients (acute stage) and the remains
were in convalescent stage. Additionally 15 pairs of sera
before and after the subsequent development of HCC were
tested. Sera were stored at -20°C until analyzed.
Chemicals
Salt-free lyophilized powder of LCA (L-5880) was purchased
from Sigma Chemical Company, St. Louis, Mo. USA. Other
reagents were of analytical grade.
Antiserum
Monospecific antiserum against human AAT was purchased
from Behringwerke AG, Marburg, W. Germany.
Serum AAT concentration
Serum AAT concentration was determined
immunodiffusion. The normal range is
282 mgdl - 1.
by single radial
from 174 to
Patients and methods
Patients
Sera of 246 subjects from 6 groups were used. As
summarized in Table I, 33 patients with acute virus hepatitis
Crossed immuno-affinity electrophoresis
Crossed immuno-affinity electrophoresis in 1% agarose in
0.02 M barbital buffer (pH 8.6) containing 0.5mgml- of
soluble LCA was performed according to the method of
B0g-Hansen (1973). Serial dilutions of the serum samples
were subjected to electrophoresis with 10mM phosphate
buffer (pH7.0) containing 0.15 M NaCl from 1 part in 16 to
1 in 64 depending on the serum concentrations of AAT. In
the first dimension, 10p of a diluted serum sample was run
at 10Vcm-1 for 3h. Then, electrophoresis in the second
K
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Table I Summary of immunochemical determinations
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
Disease category Acute Chronic Liver Hepatocellular Carcinoma Normal
virus hepatitis cirrhosis carcinoma metastatic control
hepatitis to the liver
Number of subjects 33 33 54 71 23 32
Serum AAT concentrationa (mgml M 1) 268+59 259+60 225+40 294+90 374+ 118 218+32
(range) (190-392) (152-389) (125-343) (155-560) (175-660) (171-273)
LCA-reactive species of AAT2(%) 15+5 10+5 13+5 19+9 19+ 11 8+4
(range) (4-28) (4-20) (3-23) (3-51) (7-46) (1-16)
aThe values represent mean values+s.d.
dimension was performed at 2Vcm- 1 for 20 h in an
antibody containing gel. The area under the peak of
immunoprecipitation after the second dimension run was
quantitated..by cutting out the peak from a photocopy and
weighing the paper.
Phenotyping ofAAT
AAT phenotypes were determined by polyacrylamide gel slab
isoelectric focusing in the above 15 pairs of serum samples
by the method of Arnaud et al. (1977).
The anatomic extent ofHCC
The anatomic extent of HCC was defined as follows,
according to the definition of Liver Cancer Study Group of
Japan.
Stage El <20%; stage E2 20-40%; stage E3 40-60%; and
stage E4 >60% liver involvement.
Statistical analysis
Statistical analyses were performed by using the unpaired t-
test. Data are presented as mean values+s.d. in the text.
Results
Crossed immuno-affinity electrophoresis patterns ofAAT
Two species of AAT were detected on crossed immuno-
affinity electrophoresis in a gel containing LCA. Migration
of one of the two AAT species was retarded (LCA-reactive
species) and that of the other remained unchanged (LCA-
nonreactive species). When crossed immuno-affinity
electrophoresis in each gel containing 0.1, 0.3, 0.5 and
1.0mgml -1 ofsoluble LCA was performed, the best immuno-
precipitation pattern was obtained in the gel containing
0.5mgml 'of soluble LCA, as shown in Figure 1. Therefore,
we adopted the gel containing 0.5mgml-P of soluble LCA
in the first dimension.
Typical crossed immuno-affinity electrophoresis patterns
of AAT of a patient with liver cirrhosis and a patient with
HCC are shown in Figure 2. The percentage of LCA-reactive
species of AAT in HCC was markedly higher than that in
cirrhosis.
LCA-reactive species ofAAT and serum AAT concentration
As shown in Figure 3 and Table I, the percentages of LCA-
reative species of AAT in neoplastic diseases of the liver
were significantly higher than those in benign liver diseases
and normal controls (group 4 vs. group 1, P<0.01; group 4
vs. group 2, 3 and 6, P<0.001; group 5 vs. group 1, P<0.1;
group 5 vs. group 3, P<0.02; group 5 vs. group 2 and 6,
P<0.001). Furthermore, in HCC, there were 9 patients
whose serum AFP concentrations were <10ngml-1. Three
(33%) of them showed over 30% of LCA-reactive species of
AAT.
Figure 1 Crossed immuno-affinity electrophoresis patterns of
AAT in the presence of various concentrations of LCA (a,
0.lmgml-; b, 0.3mgml-1; c, 0.5mgml-1; d, 1.Omgml-1).
Serum AAT concentrations in neoplastic diseases of the
liver were also significantly higher than those in benign liver
diseases and normal controls (group 5 vs. group 1, 2, 3, 4
and 6, P<0.001: group 4 vs. group 2, P<0.05; group 4 vs.
group 3 and 6, P<0.001). Details are given in Table I
and Figure 4. However, there was no correlation between
the percentage of LCA-reactive species of AAT and serum
AAT concentration in any group (group 1, r=0.204,
y=0.018x+ 10.17; group 2, r=-0.171, y=-0.013x+ 13.38;
group 3, r= -0.042, y= -0.005x+ 14.57; group 4, r=0.040,
y=0.004x+ 18.17; group 5, r=0.296, y=0.024x+9.878;
group 6, r=0.127, y=0.016x+5.191). In HCC especially, 10
(34%) of 29 patients whose serum AAT concentrations were
within the normal range showed more than 20% of LCA-
reactive species of AAT.
When we compared LCA-reactive species of AAT in the
acute stage of acute virus hepatitis with that in the
convalescent stage, there was no significant difference
between them (acute stage, 16+4%; convalescent stage,
14+6%). However, serum AAT concentration in the acute
stage (302 +43mgdl-1) was significantly higher than that in
convalescence (232+54mgdl-1, P<0.001). Additionally,
there was no significant difference between chronic active
hepatitis and chronic inactive- hepatitis patients in either
LCA-reactive species of AAT or serum AAT concentration.
Next, we tested 15 pairs of serum samples from patients
with a long history of chronic liver diseases before and after
the subsequent development ofHCC. The percentage ofLCA-MICROHETEROGENEITY OF AAT IN LIVER DISEASES
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Figure 4 Serum AAT concentration in the six patient groups.
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Figure 2 Crossed immuno-affinity electrophoresis patterns of
AAT of a patient with liver cirrhosis (a) and a patient with
HCC (b).
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Figure 3 The percentage of LCA-reactive species of AAT in the
six patient groups. Solid circles represent individual values and
vertical bars indicate mean +s.d.
Figure 5 Serum AAT concentration and the percentage of
LCA-reactive species ofAAT before and after the development of
HCC.
reactive species of AAT after HCC development (21+9%)
was significantly higher than before (11+5%, P<0.001),
although there was no significant difference in serum AAT
concentrations before (225 +30mgdl-1) and afterwards
(252+52 mgdl 1) (Figure 5).
Phenotyping ofAAT
Polyacrylamide gel slab isoelectric focusing was performed to
determine AAT phenotypes in the above 15 pairs of serum
samples. All of the phenotypes were PiMM and no change in
phenotype was observed before and after the development of
HCC. PiMM subtypes were M 1M l (11 patients), M1M2 (2)
and M2M3 (2).
Relationship between LCA-reactive species ofAAT and the
anatomic extent ofHCC
We investigated the relationship between the percentage of
LCA-reactive species of AAT and the anatomic extent of
HCC (stage El, E2, E3 and E4). The percentage of LCA-
reactive species of AAT in stage E4 (28 + 13%) was
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statistically greater than those in the others (stage El,
19+9%; stage E2, 15+5%; stage E3, 17+6%, P<0.05).
Serum AAT concentration was 258+96mgdl-1 in stage
El, 303+94mgdl-1 in stage E2, 324+80mgdl-P in stage
E3 and 302+82mgdl-1 in stage E4. There was no clear
difference among them.
Comparison ofLCA-reactive species ofAAT and AFP
When we compared LCA-reactive species of AAT with that
of AFP in 49 patients with HCC, there was no correlation
between them (r=0.218, y=0.738x+28.82). Thirty-five
patients (71%) showed over 20% of LCA- reactive species of
AFP and 23 patients (47%) showed over 20% of that of
AAT. Forty-two patients (86%) showed over 20% of LCA-
reactive species of AFP or AAT.
Changes in LCA-reactive species ofAAT
Changes in LCA-reactive species of AAT were followed up
in 5 patients with liver cirrhosis. Sequential serum samples
from the period of cirTrhosis until the subsequent
development of HCC were analysed. HCC was detected by
elevation of LCA-reactive species of AAT in 2 patients (nos.
I and 2) whose serum AFP concentrations were within the
normal range. In patient 3, LCA-reactive species of AAT
was unchanged when HCC was found, but increased with
tumour progression. In patient 4, LCA-reactive species of
AAT increased slightly when HCC was detected, and
decreased after surgical resection. In patient 5, LCA-reactive
species of AAT remained unchanged even after HCC
developed. These data are illustrated in Figure 6.
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Figure 6 Changes in the percentage of LCA-reactive species of
AAT in sequential serum samples from 5 patients with liver
cirrhosis. The arrow indicates clinical verification of HCC.
Discussion
Our previous studies have shown that measurement of LCA-
reactive species of AFP is much more useful than that of
serum AFP concentration for the early diagnosis of HCC
and that it can distinguish an AFP species due to HCC from
one due to benign liver diseases. The molecular basis for this
LCA-reactive species of AFP is fucosylation of the sugar
chain (Aoyagi et al., 1984, 1985a,b, 1986). We therefore
tested the reactivity of AAT with LCA in order to
investigate whether use could be made of the microhetero-
geneity of serum AAT for the diagnosis of HCC. The
percentages of LCA-reactive species of AAT in HCC and
carcinoma metastatic to the liver were significantly higher
than those in benign liver diseases such as acute virus
hepatitis, chronic hepatitis, and liver cirrhosis, and normal
controls. No correlation was found between the percentage
of LCA-reactive species of AAT and serum AAT
concentration.
From the above results and several reports (Palmer &
Wolfe, 1976; Palmer et al., 1980; Ord6fiez & Manning, 1984)
that immunoreactive AAT is present in HCC cells by the
immunoperoxidase method, it was suggested that HCC cells
might produce AAT, of an abnormal type i.e., that the
change in the reactivity of AAT with LCA occurs in
association with neoplastic transformation of hepatocytes,
irrespective of serum AAT concentration. During the follow-
up of the patients with chronic liver diseases, measurement
of LCA-reactive species of AAT might thus be useful for the
diagnosis of HCC, especially when serum AFP concentration
is within the normal range. In fact, elevation of LCA-
reactive species of AAT led us to find HCC in some patients
with liver cirrhosis.
The LCA-reactive species of AFP is known to contain a
carbohydrate chain of the fucosylated biantennary complex
type and most of the patients with HCC are known to have
an elevated serum concentration of fucosylated AFP (Aoyagi
et al., 1984, 1985a,b, 1986). Since a carbohydrate structure
of AAT is similar to that of AFP (Mega et al., 1980), LCA-
reactive species of AAT is supposed to be a fucosylated
fraction.
A characteristic feature of AAT is the multiple banding
that is shown by isoelectric focusing. This banding is the
result of microheterogeneity due to variations in its
carbohydrate structure and a single amino acid substitution
(Carell et al., 1982). Therefore in order to investigate
whether AAT phenotypes might change before and after the
subsequent development of HCC, polyacrylamide gel slab
isoelectric focusing was performed, using 15 pairs of serum
samples. The result showed that all of the phenotypes were
PiMM and that no change in phenotype was observed. In
reference to the subtypes, PiM2M3, thought to be a pre-
disposing factor to developing to chronic liver disease, was
detected in 2 cases (13%) and this frequency was consistent
with that of an earlier report (Miyake et al., 1980).
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